AU2008331545B2 - Recombinantly modified plasmin - Google Patents

Recombinantly modified plasmin Download PDF

Info

Publication number
AU2008331545B2
AU2008331545B2 AU2008331545A AU2008331545A AU2008331545B2 AU 2008331545 B2 AU2008331545 B2 AU 2008331545B2 AU 2008331545 A AU2008331545 A AU 2008331545A AU 2008331545 A AU2008331545 A AU 2008331545A AU 2008331545 B2 AU2008331545 B2 AU 2008331545B2
Authority
AU
Australia
Prior art keywords
polypeptide
plasmin
plasminogen
amino acid
tal6003
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008331545A
Other languages
English (en)
Other versions
AU2008331545A1 (en
Inventor
Valery Novokhatny
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grifols Therapeutics LLC
Original Assignee
Grifols Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grifols Therapeutics LLC filed Critical Grifols Therapeutics LLC
Publication of AU2008331545A1 publication Critical patent/AU2008331545A1/en
Assigned to Grifols Therapeutics Inc. reassignment Grifols Therapeutics Inc. Alteration of Name(s) of Applicant(s) under S113 Assignors: TALECRIS BIOTHERAPEUTICS, INC.
Application granted granted Critical
Publication of AU2008331545B2 publication Critical patent/AU2008331545B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2008331545A 2007-11-29 2008-11-25 Recombinantly modified plasmin Active AU2008331545B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99114807P 2007-11-29 2007-11-29
US60/991,148 2007-11-29
PCT/US2008/084645 WO2009073471A1 (en) 2007-11-29 2008-11-25 Recombinantly modified plasmin

Publications (2)

Publication Number Publication Date
AU2008331545A1 AU2008331545A1 (en) 2009-06-11
AU2008331545B2 true AU2008331545B2 (en) 2014-01-16

Family

ID=40379999

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008331545A Active AU2008331545B2 (en) 2007-11-29 2008-11-25 Recombinantly modified plasmin

Country Status (17)

Country Link
US (3) US8101394B2 (cg-RX-API-DMAC10.html)
EP (1) EP2220221B1 (cg-RX-API-DMAC10.html)
JP (1) JP5539896B2 (cg-RX-API-DMAC10.html)
KR (1) KR101529743B1 (cg-RX-API-DMAC10.html)
CN (1) CN101918548B (cg-RX-API-DMAC10.html)
AU (1) AU2008331545B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0819780B1 (cg-RX-API-DMAC10.html)
CA (1) CA2707266C (cg-RX-API-DMAC10.html)
ES (1) ES2534040T3 (cg-RX-API-DMAC10.html)
HU (1) HUE024916T2 (cg-RX-API-DMAC10.html)
IL (1) IL205936A (cg-RX-API-DMAC10.html)
MX (1) MX2010005947A (cg-RX-API-DMAC10.html)
NZ (2) NZ593837A (cg-RX-API-DMAC10.html)
PL (1) PL2220221T3 (cg-RX-API-DMAC10.html)
PT (1) PT2220221E (cg-RX-API-DMAC10.html)
WO (1) WO2009073471A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201003730B (cg-RX-API-DMAC10.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2246417T3 (pl) 2004-04-22 2015-06-30 Grifols Therapeutics Inc Rekombinacyjnie zmodyfikowana plazmina
US8101394B2 (en) 2007-11-29 2012-01-24 Grifols Therapeutics Inc. Recombinantly modified plasmin
UA103771C2 (ru) 2008-06-04 2013-11-25 Грифолз Терапьютикс Инк. Стрептокиназа, активирующая плазмин, способ и набор для получения плазмина
JP5789521B2 (ja) * 2009-03-03 2015-10-07 グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． プラスミノーゲンを製造するための組成物、方法およびキット；ならびにそれから製造されるプラスミン
NZ597452A (en) 2009-07-10 2013-10-25 Thrombogenics Nv Variants of plasminogen and plasmin
WO2011023805A1 (en) 2009-08-28 2011-03-03 Thrombogenics N.V. Use of plasmin for the treatment of filtration failure after trabeculectomy
CN102121023B (zh) * 2010-12-22 2012-07-04 中山大学 突变型人纤溶酶原kringle5及其制备方法及应用
CA2823491A1 (en) 2011-01-05 2012-07-12 Thrombogenics Nv Plasminogen and plasmin variants
CA2844644A1 (en) 2011-08-12 2013-02-21 Thrombogenics N.V. Plasminogen and plasmin variants
CN103205410B (zh) * 2012-01-13 2018-03-06 蔺莹莹 重组微纤维蛋白溶酶及其制备方法和应用
KR20150127202A (ko) 2013-03-14 2015-11-16 바이엘 헬스케어 엘엘씨 헤파린과 복합체화된 항트롬빈 베타에 대한 모노클로날 항체
DE102014112212A1 (de) * 2014-08-26 2016-03-03 Akesion Gmbh Rekombinante Fusionsproteine zur Vorbeugung oder Behandlung von Adhäsionen bei Geweben oder Organen
FR3035120B1 (fr) * 2015-04-15 2020-02-07 Arcadophta Composition de plasminogenase immobilisee, procede de preparation, utilisation et dispositif comprenant une telle composition
WO2017101871A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种预防和治疗心血管病的新方法
JP2019500426A (ja) 2015-12-18 2019-01-10 タレンゲン インターナショナル リミティッドＴａｌｅｎｇｅｎ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ 糖尿病網膜症を予防または治療するための方法
TWI653981B (zh) 2015-12-18 2019-03-21 深圳瑞健生命科學硏究院有限公司 Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury
EP3395354B1 (en) 2015-12-18 2024-05-22 Talengen International Limited Plasminogen for use in treating diabetic nephropathy
TWI677348B (zh) 2016-12-15 2019-11-21 大陸商深圳瑞健生命科學研究院有限公司 一種改善心臟病變的方法
CN108210897A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗肺纤维化的药物及其用途
WO2018107701A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种新的降血糖和提高糖耐量的药物
TWI750189B (zh) * 2016-12-15 2021-12-21 大陸商深圳瑞健生命科學研究院有限公司 一種治療冠狀動脈粥樣硬化及其併發症的方法
JP7213552B2 (ja) 2016-12-15 2023-01-27 タレンゲン インターナショナル リミテッド 肝の繊維化を予防及び治療するための方法
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
CA3067890A1 (en) 2017-06-19 2018-12-27 Talengen International Limited Method for regulating and controling glp-1/glp-1r and drug
US11140020B1 (en) 2018-03-01 2021-10-05 Amazon Technologies, Inc. Availability-enhancing gateways for network traffic in virtualized computing environments
US12226462B2 (en) 2019-01-25 2025-02-18 Council Of Scientific & Industrial Research Fibrinolytic composition and method of its preparation
KR20230005298A (ko) 2020-05-11 2023-01-09 탈렌젠 인터내셔널 리미티드 척수성 근위축증의 치료 방법 및 약물
CN118308334B (zh) * 2024-06-06 2024-10-08 深圳市卫光生物制品股份有限公司 一种重组人纤溶酶原及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002050290A1 (en) * 2000-12-21 2002-06-27 Thromb-X Nv A yeast expression vector and a method of making a recombinant protein by expression in a yeast cell
WO2004052228A2 (en) * 2002-12-06 2004-06-24 Thromb-X Nv Pharmacological vitreolysis
WO2005105990A2 (en) * 2004-04-22 2005-11-10 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
WO2007047874A2 (en) * 2005-10-20 2007-04-26 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652639A (en) * 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4631211A (en) * 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US4774087A (en) * 1987-08-14 1988-09-27 Northwestern University Micro-size fibrinolytic plasmin
US7253264B1 (en) * 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
CA2243560A1 (en) 1996-01-23 1997-07-31 Rapigene, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
US6312893B1 (en) * 1996-01-23 2001-11-06 Qiagen Genomics, Inc. Methods and compositions for determining the sequence of nucleic acid molecules
US6613508B1 (en) * 1996-01-23 2003-09-02 Qiagen Genomics, Inc. Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques
JPH10158300A (ja) * 1996-11-28 1998-06-16 Suzuki Motor Corp 血管新生抑制効果を有するタンパク質とその製造方法及びアンギオスタチンの製造方法
NZ501774A (en) * 1997-07-22 2002-02-01 Qiagen Genomics Inc Computer method and system for correlating known characteristics of biomolecules to molecular tags with unique molecular weights that are associated with the biomolecule
WO2000003726A1 (en) * 1998-07-14 2000-01-27 Bristol-Myers Squibb Company Lysine binding fragments of angiostatin
ES2276536T3 (es) * 1998-09-29 2007-06-16 LEUVEN RESEARCH & DEVELOPMENT VZW Uso de compuestos que reducen las alfas2-antiplasminas in vivo para la preparacion de una composicion para el tratamiento del ictus isquemico.
US6964764B2 (en) * 1999-11-13 2005-11-15 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6355243B1 (en) * 1999-11-13 2002-03-12 Bayer Corporation Method of thrombolysis by local delivery of active plasmin
US6969515B2 (en) * 1999-11-13 2005-11-29 Talecris Biotherapeutics, Inc. Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6664112B2 (en) * 2000-06-02 2003-12-16 Blue Heron Biotechnology, Inc. Methods for improving the sequence fidelity of synthetic double-stranded oligonucleotides
AU2002357249A1 (en) 2001-12-13 2003-07-09 Blue Heron Biotechnology, Inc. Methods for removal of double-stranded oligonucleotides containing sequence errors using mismatch recognition proteins
US7776026B2 (en) * 2002-02-06 2010-08-17 Nuvue Technologies, Inc. Method for vitreous liquefaction
US20050124036A1 (en) * 2002-02-06 2005-06-09 Rudy Susilo Method for producing recombinant proteins in micro-organisms
US8101394B2 (en) 2007-11-29 2012-01-24 Grifols Therapeutics Inc. Recombinantly modified plasmin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002050290A1 (en) * 2000-12-21 2002-06-27 Thromb-X Nv A yeast expression vector and a method of making a recombinant protein by expression in a yeast cell
WO2004052228A2 (en) * 2002-12-06 2004-06-24 Thromb-X Nv Pharmacological vitreolysis
WO2005105990A2 (en) * 2004-04-22 2005-11-10 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin
WO2007047874A2 (en) * 2005-10-20 2007-04-26 Talecris Biotherapeutics, Inc. Recombinantly modified plasmin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MEDYNSKI D et al, Protein Expression and Purification, 2007, 52:395-402 *

Also Published As

Publication number Publication date
US8101394B2 (en) 2012-01-24
KR101529743B1 (ko) 2015-06-17
NZ593837A (en) 2013-01-25
US8182808B2 (en) 2012-05-22
AU2008331545A1 (en) 2009-06-11
NZ585715A (en) 2011-11-25
ES2534040T3 (es) 2015-04-16
CA2707266A1 (en) 2009-06-11
BRPI0819780B1 (pt) 2023-01-24
WO2009073471A1 (en) 2009-06-11
CA2707266C (en) 2013-12-31
EP2220221A1 (en) 2010-08-25
EP2220221B1 (en) 2014-12-31
BRPI0819780A2 (pt) 2015-08-11
PL2220221T3 (pl) 2015-07-31
US20120093799A1 (en) 2012-04-19
JP5539896B2 (ja) 2014-07-02
KR20100102135A (ko) 2010-09-20
US8512980B2 (en) 2013-08-20
MX2010005947A (es) 2010-09-10
CN101918548B (zh) 2013-10-16
US20120276611A1 (en) 2012-11-01
JP2011505140A (ja) 2011-02-24
CN101918548A (zh) 2010-12-15
HUE024916T2 (en) 2016-02-29
IL205936A0 (en) 2010-11-30
PT2220221E (pt) 2015-04-16
IL205936A (en) 2015-04-30
US20110003332A1 (en) 2011-01-06
ZA201003730B (en) 2012-11-28
HK1146089A1 (en) 2011-05-13

Similar Documents

Publication Publication Date Title
US8101394B2 (en) Recombinantly modified plasmin
US8420079B2 (en) Recombinantly modified plasmin
HK1146089B (en) Recombinantly modified plasmin
HK1099341B (en) Recombinantly modified plasmin
HK1150242B (en) Recombinantly modified plasmin
HK1175812B (en) Recombinantly modified plasmin

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)